Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
- 31 August 2005
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 150 (2) , 323-329
- https://doi.org/10.1016/j.ahj.2004.08.037
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- COMPARISON OF HOSPITAL COSTING METHODS IN AN ECONOMIC EVALUATION OF A MULTINATIONAL CLINICAL TRIALInternational Journal of Technology Assessment in Health Care, 2003
- Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and designAmerican Heart Journal, 2000
- Resource costing for multinational neurologic clinical trials: methods and resultsHealth Economics, 1998
- Modeling Valuations for EuroQol Health StatesMedical Care, 1997
- Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarctionEuropean Heart Journal, 1997
- A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1995
- Cost-effectiveness of captopril therapy after myocardial infarctionJournal of the American College of Cardiology, 1995
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995
- Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1992
- Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical AccuracyStatistical Science, 1986